Wall Street brokerages expect that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will announce earnings of ($0.07) per share for the current quarter, according to Zacks. Four analysts have issued estimates for Ironwood Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.03) and the lowest estimate coming in at ($0.19). Ironwood Pharmaceuticals reported earnings per share of ($0.28) during the same quarter last year, which indicates a positive year-over-year growth rate of 75%. The company is scheduled to issue its next quarterly earnings report after the market closes on Monday, August 5th.

According to Zacks, analysts expect that Ironwood Pharmaceuticals will report full-year earnings of ($0.16) per share for the current fiscal year, with EPS estimates ranging from ($0.33) to $0.06. For the next financial year, analysts expect that the business will report earnings of $0.56 per share, with EPS estimates ranging from $0.17 to $1.13. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.10). The business had revenue of $68.73 million for the quarter, compared to analysts’ expectations of $81.93 million. During the same quarter last year, the firm earned ($0.25) earnings per share. Ironwood Pharmaceuticals’s revenue was down .6% on a year-over-year basis.

Several research firms have weighed in on IRWD. BidaskClub upgraded shares of Zai Lab from a “buy” rating to a “strong-buy” rating in a report on Friday, June 28th. HC Wainwright set a $126.00 price objective on shares of AnaptysBio and gave the stock a “buy” rating in a report on Monday, June 24th. Mizuho set a $20.00 price objective on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, May 2nd. Zacks Investment Research downgraded shares of Great Portland Estates from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. Finally, ValuEngine downgraded shares of Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $15.05.

In other news, CFO Gina Consylman sold 4,055 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $10.53, for a total value of $42,699.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.90% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Norges Bank purchased a new position in shares of Ironwood Pharmaceuticals during the fourth quarter worth approximately $19,568,000. Northern Trust Corp grew its holdings in shares of Ironwood Pharmaceuticals by 2.0% in the fourth quarter. Northern Trust Corp now owns 1,712,129 shares of the biotechnology company’s stock worth $17,738,000 after purchasing an additional 33,007 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Ironwood Pharmaceuticals by 6.0% in the fourth quarter. Geode Capital Management LLC now owns 1,658,754 shares of the biotechnology company’s stock worth $17,184,000 after purchasing an additional 94,453 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Ironwood Pharmaceuticals by 425.5% in the fourth quarter. Millennium Management LLC now owns 1,373,080 shares of the biotechnology company’s stock worth $14,225,000 after purchasing an additional 1,111,814 shares during the last quarter. Finally, Peregrine Capital Management LLC bought a new position in shares of Ironwood Pharmaceuticals in the second quarter worth approximately $13,487,000. 98.89% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:IRWD traded up $0.06 during trading on Tuesday, reaching $10.72. The stock had a trading volume of 967,381 shares, compared to its average volume of 1,204,881. The business’s fifty day moving average is $10.79. Ironwood Pharmaceuticals has a 52 week low of $9.07 and a 52 week high of $20.33. The stock has a market capitalization of $1.66 billion, a PE ratio of -11.28 and a beta of 1.68.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.

Further Reading: What are the advantages of the Stochastic Momentum Index?

Get a free copy of the Zacks research report on Ironwood Pharmaceuticals (IRWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.